中国临床药理学杂志2017，Vol.33Issue(8)：684-686,3.DOI:10.13699/j.cnki.1001-6821.2017.08.004
贝伐单抗联合吉非替尼片治疗非小细胞肺癌的临床研究
Clinical trial of bevacizumab combined with gefitinib tablets in the treatment of non-small cell lung adenocarcinoma
摘要
Abstract
Objective To observe the clinical efficacy and safety of bevacizumab combined with gefitinib tablets in the treatment of non-small cell lung adenocarcinoma.Methods Ninety patients with non-small cell lung adenocarcinoma were divided into control group (n =45 cases) and treatment group(n =45 cases) according to random method.Control group was given oral gefitinib,250 mg qd.Treatment group was given intravenous drip of bevacizumab 7.5 mg · kg-1,qd,on the basis of control group.Two groups were treated for 3 cycles with 21 days per cycle.The clinical efficacy,the levels of vascular endothelial growth factor(VEGF) and its receptor(KDR),matrix metalloproteinase 9 (MMP-9) and epithelial type adhesive(E-cad),and the occurrence of adverse drug reactions were observed.Results After treatment,the total effective rates in treatment and control groups were 77.78％ (35/45 cases)and 57.78％ (26/45 cases) with statistically significant difference (P ＜ 0.05).After treatment,the main indexes in the treatment and control groups were compared:the levels of VEGF were(0.76-±0.08) and(1.47 ±0.11),KDR were (0.65 ±0.13) and(0.81 ±0.14),MMP-9 were(0.87 ±0.15) and(1.11 ±0.15),E-cad were (1.58 ± 0.16) and (1.32 ± 0.14),the differences were statistically significant(P ＜ 0.05).The adverse drug reactions were mainly skin rashes,diarrhea and headache in treatment group,which in control group were skin rashes and diarrhea.The incidences of adverse drug reactions were 22.22％ and 15.56％ in treatment and control groups without significant difference (P ＞ 0.05).Conclusion Bevacizumab combined with gefitinib tablets has a definitive clinical efficacy in the treatment of non-small cell lung adenocarcinoma,without increasing the incidence of adverse drug reactions.关键词
贝伐单抗/吉非替尼片/非小细胞肺癌/血管内皮细胞生长因子/安全性Key words
bevacizumab/gefitinib tablet/non-small cell lung adenocarcinoma/vascular endothelial growth factor/safety分类
医药卫生引用本文复制引用
徐彩虹,陈俊..贝伐单抗联合吉非替尼片治疗非小细胞肺癌的临床研究[J].中国临床药理学杂志,2017,33(8):684-686,3.基金项目
宁波市自然科学基金资助项目(2012A610199) （2012A610199）
